Working... Menu

BAROSTIM THERAPY™ In Resistant Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02880631
Recruitment Status : Recruiting
First Posted : August 26, 2016
Last Update Posted : February 28, 2018
Information provided by (Responsible Party):
CVRx, Inc.

Brief Summary:
The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.

Condition or disease Intervention/treatment
Hypertension Device: Barostim Neo™ System

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: BAROSTIM THERAPY™ In Resistant Hypertension: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System
Study Start Date : August 2016
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Blood Pressure Changes from Baseline to 6 Months Post-Implant [ Time Frame: Baseline, 6 months post-implant ]
  2. Cardiovascular Medication Changes from Baseline to 6 Months Post-Implant [ Time Frame: Baseline, 6 months post-implant ]
    Medication name, dose, frequency, and start/stop date will be assessed over the 6 month time interval.

  3. Number of Hospitalizations over Follow-Up [ Time Frame: 12 months post-implant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects can be included in the Hypertension Registry if they were implanted in the past 30 days and meet the CE-Mark approved indications and contraindications for the BAROSTIM NEO System in the treatment of resistant hypertension.

Inclusion Criteria:

  • Has signed an EC approved informed consent form
  • Has been implanted with the BAROSTIM NEO system in the past 30 days
  • Systolic blood pressure greater than or equal to 140 mmHg, and
  • Resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications

Exclusion Criteria:

  • Bilateral carotid bifurcations located above the level of the mandible
  • Baroreflex failure or autonomic neuropathy
  • Uncontrolled, symptomatic cardiac bradyarrhythmias
  • Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50%
  • Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02880631

Layout table for location contacts
Contact: CVRx Vice President of Clinical Research 763-416-2876

Layout table for location information
Immanual Kilikum Bernau Recruiting
Bernau, Germany, 16321
Contact: Daniela Bettin    +49-3338-694604   
Principal Investigator: Christian Butter         
St. Josefs-Hospital Cloppenburg gemainnutzige gGmbH Recruiting
Cloppenburg, Germany, 49661
Contact: Ulla Venneklaas    +49 4471-16 2955   
Principal Investigator: Stephan Luders         
Cardiovascular Center 'CVC' Frankfurt Recruiting
Frankfurt, Germany, 60398
Contact: Sabine De Bruijn    +49 69 97347653   
Principal Investigator: Horst Sievert         
Justus-Leibig University Giessen Recruiting
Gießen, Germany, 35392
Contact: Gabriele Hellwig    0641-985-42632   
Principal Investigator: Jorn Schmitt         
Hamburg - Asklepios Kliniken Recruiting
Hamburg, Germany, 20099
Contact: Christine Neumann    +49 401818818635   
Principal Investigator: Jochen Muller-Ehmsen         
Schleswig-Hostein Campus Kiel Recruiting
Kiel, Germany, 24105
Contact: Anika Struve    +49-431-500-22915   
Principal Investigator: Hendrik Bonnemeier         
University Hospital of Cologne Recruiting
Köln, Germany, 50937
Contact: Tatjana Schewior    +49-221-478-88273   
Principal Investigator: Hannes Reuter         
Universitat Leipzig Recruiting
Leipzig, Germany, 04109
Contact: Jenny Dietrich    +49 (341) 97 12 408   
Contact: Janine Starke    +49 (341) 97 12 443f   
Principal Investigator: Martin Neef         
Kilnikum Lippe GmbH Recruiting
Lippe, Germany, 32756
Contact: Melanie Kriete    05231 172-5727   
Principal Investigator: Kirk Haertel         
Marien-Krankenhaus Seigen gem. GmbH Recruiting
Siegen, Germany, 57072
Contact: Christopher Blanke    02711-231-1215   
Principal Investigator: Michael Buerke         
Hospital and MVS Maria-Hilf Stadtlohn GmbH Recruiting
Stadtlohn, Germany, 489703
Contact: Britta Fitz    02563-912-6370   
Principal Investigator: Alessandro Cuneo         
Klinikum Landkreis Tuttlingen Recruiting
Tuttlingen, Germany, 78532
Contact: Ida Weber    07461 97 1415   
Principal Investigator: Michael Kotzerke         
Heinrich-Braun Klinikum Recruiting
Zwickau, Germany, 08060
Contact: Heike Plottner    0375512138   
Principal Investigator: Jens Gerth         
Clinical Trial Center Maastricht, B.V. Recruiting
Maastricht, Netherlands, 6229
Contact: Heidi Jongen    +31-43-3877366   
Principal Investigator: Bram Kroon         
Sponsors and Collaborators
CVRx, Inc.
Layout table for investigator information
Study Chair: Hannes Reuter, PhD Herzzentrum Uniklinik Köln

Additional Information:

Layout table for additonal information
Responsible Party: CVRx, Inc. Identifier: NCT02880631     History of Changes
Other Study ID Numbers: 360051-001
First Posted: August 26, 2016    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases